Ovid Therapeutics (OVID) Change in Accured Expenses (2016 - 2026)

Ovid Therapeutics (OVID) has reported Change in Accured Expenses for 11 consecutive years, with -$352000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 88.81% year-over-year to -$352000.0; the trailing twelve-month figure through Jun 2026 stood at $325000.0 (up 106.17% YoY), and the FY2025 full-year result was -$1.1 million, down 98.88% from the prior year.
• Change in Accured Expenses grew to -$352000.0 in Q2 2026 per OVID's latest filing, from -$1.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.1 million in Q2 2024 and bottomed at -$3.4 million in Q2 2022.
• Historically, Change in Accured Expenses has averaged -$250255.9 across 5 years, with a median of -$176500.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses surged 229.55% in 2025, then slumped 140100.0% in 2026.
• Over 5 years, Change in Accured Expenses stood at -$1.2 million in 2022, then soared by 125.36% to $303000.0 in 2023, then slumped by 622.77% to -$1.6 million in 2024, then soared by 229.55% to $2.1 million in 2025, then tumbled by 117.15% to -$352000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$352000.0, -$1.4 million, and $2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.